EGFR and non-small cell lung carcinoma: Over the past decade, tyrosine kinase inhibitors (TKIs) have made significant advances in the treatment of cancer, especially NSCLC.EGFR-TKI, as a potent agent for the treatment of over-activation of EGFR signalling, has been developed for multiple generations with remarkable efficacy (54, 65).